Two United States Patent and Trademark Office (USPTO) patents have been granted to AlloSource on Dec. 29th 2015 for cartilage repair allografts. AlloSource is one of the principal providers of cartilage, cellular, bone, skin and soft-tissue allografts, which are importantly employed in surgical procedures and for wound care to advance the process of healing in patients.
The Granted Patents: The first patent entitled “Perforated osteochondral allograft compositions” with U.S. Patent Number 9,168,140, deals with donated osteochondral tissue with a bone and cartilage layer perforated with small holes to allow for cellular migration and osteochondral repair. The second patent entitled “Minced cartilage systems and methods” with U.S. Patent Number 9,186,380, covers up donated cartilage tissue processed to include small particles of cartilage containing living chondrocytes.
The Company: AlloSource is a nonprofit organization with more than 400 employees founded in 1994 and responsibly deals with human tissue donation in terms of developing, processing and distributing life-saving and life-enhancing allografts. The company is accredited by the American Association of Tissue Banks and is headquartered in Centennial, CO. The company presents more than 200 types of accurate bone, skin, soft-tissue and custom-machined allografts for numerous application in medical procedures, which can save one’s life. Furthermore, the company ranks as the world’s leader in fresh cartilage tissue used for joint repair and skin allografts for the purpose of healing severe burns. The company is the world’s largest processor of cellular bone allografts and delivers unparalleled expertise and customer service to surgeons, partners and to the country’s most reputable Organ Procurement Organizations. AlloSource is also one of the leading innovators in intensifying tissue donation with an objective of presenting best possible solutions for healthcare providers and their patients. For more than 20 years, AlloSource has offered products in various areas with respect to advanced technology of cells, offering life-saving and life-enhancing possibilities in spine, sports medicine, foot and ankle, orthopedic, reconstructive, trauma and wound care procedures. The company’s safety and tissue processing standards meet and exceed guidelines set forth by the United States Food and Drug Administration (FDA) and the American Association of Tissue Banks (AATB).
The current international communities of AlloSource include The Asian Pacific Rim, The European Union, North America, Latin America and South America.
As per Thomas Cycyota, AlloSource president and CEO. “The continued expansion of our intellectual property portfolio illustrates our dedication to growth and innovation,” and “AlloSource is passionate about developing new solutions for the medical community and will continue to be motivated by finding ways to honor the gift of human tissue donation by helping patients heal.” The mission of AlloSource is to persistently perfecting and pursuing innovations in their products and processes and to expand capability to deliver life-saving and life-enhancing allografts to more individuals in need.
